Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Study to Investigate the Safety and Immunogenicity of Cam2020 (A/Cambodia/e0826360/2020) M2SR H3N2 Monovalent Influenza Vaccine Administered Alone or With Licensed, Inactivated Influenza Vaccine in Adults 65 to 85 Years Old

NCT05163847 is registered in ClinicalTrials.gov with FluGen Inc as lead sponsor.

NCT NCT05163847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05163847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Study to Investigate the Safety and Immunogenicity of Cam2020 (A/Cambodia/e0826360/2020) M2SR H3N2 Monovalent Influenza Vaccine Administered Alone or With Licensed, Inactivated Influenza Vaccine in Adults 65 to 85 Years Old
Lead sponsor
FluGen Inc
Phase
Phase 1
Overall status
Completed
Start date
June 14, 2022
Completion date
November 3, 2022
Enrollment
303 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

influenza vaccine